Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ: INM )

4.950 +0.450 (+10.00%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook
Via Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at Tribe Public’s Webinar Event
Via Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Announces Publication of Article on CBN as Possible Glaucoma Treatment
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment
Via Investor Brand Network
InMed Pharmaceuticals’ (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
Via CannabisNewsWire
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Cannabis Conference
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
InMed Pharmaceuticals (INM): Progress Across the Business
LONDON, UK / ACCESSWIRE / November 17, 2021 / With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is now in its... 
From Edison Investment Research Limited
Via AccessWire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Working on Answer to Mass Production of Rare, Otherwise Depleted Cannabinoid Opportunities
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Results, Business Updates for Q1 2022
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production
Via Investor Brand Network
Topics Initial Public Offering
Exposures Securities Market
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production
Via CannabisNewsWire
Topics Initial Public Offering
Exposures Securities Market
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Completion of BayMedica Acquisition
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Completion of BayMedica Acquisition
Via CannabisNewsWire
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids
Via Investor Brand Network
Topics Supply Chain
Exposures Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids
Via CannabisNewsWire
Topics Supply Chain
Exposures Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release FY 2021 Financial Report, Acquire BayMedia
Via CannabisNewsWire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.